Richard T. Maziarz

Oregon Health & Science University

United States

This profile is automatically generated from trusted academic sources.

Google Scholar

ORCID

How do I reach out?

Meet Kite AI

Contact this professor

ORCID

Google Scholar

Research Interests

Internal Medicine

40%

Pharmacotherapy

40%

Hematology

30%

Stem Cell Transplantation

20%

Biologic Therapy

20%

Pediatric Hematology

20%

Renal Replacement Therapy

20%

Ask ApplyKite AI

Start chatting

How can you help me contact this professor?

What are this professor's research interests?

How should I write an email to this professor?

Articles7

A new beginning: can omidubicel emerge as the next, viable alternative donor source?

Article Link

Year:

2023

Hospitalization and Healthcare Resource Utilization of Omidubicel-onlv Versus Umbilical Cord Blood Transplantation for Hematologic Malignancies: Secondary Analysis From a Pivotal Phase 3 Clinical Trial

Article Link

Year:

2023

Allogeneic Hematopoietic Cell Transplantation Improves Outcome in Myelodysplastic Syndrome Across High-Risk Genetic Subgroups: Genetic Analysis of the Blood and Marrow Transplant Clinical Trials Network 1102 Study

Article Link

Year:

2023

Estimating the Lifetime Medical Cost Burden of an Allogeneic Hematopoietic Cell Transplantation Patient

Article Link

Year:

2023

Midostaurin after allogeneic stem cell transplant in patients with FLT3-internal tandem duplication-positive acute myeloid leukemia

Article Link

Year:

2021

Biologic Assignment Trial of Reduced-Intensity Hematopoietic Cell Transplantation Based on Donor Availability in Patients 50-75 Years of Age With Advanced Myelodysplastic Syndrome

Article Link

Year:

2021

Grading of neurological toxicity in patients treated with tisagenlecleucel in the JULIET trial

Article Link

Year:

2020

Collaborators1

Mark J. Levis

Johns Hopkins University

UNITED STATES

How do I reach out?

Meet Kite AI